Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838799 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 458
- Enrollment target
NCT00838799: Completed Phase 2 study, sponsored by Forest Laboratories.
NCT00838799 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 458 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (244% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00838799, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 458 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.
Interventions
- DRUG placebo
- DRUG pregabalin
- DRUG RGH-896
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2009-02 |
| Phase | Phase 2 |
What the finished NCT00838799 record still lists
NCT00838799 is an interventional study that assigns participants to a tested intervention. The registered 458 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (244% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00838799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00838799 about?
NCT00838799 is a clinical study titled "Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain". This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.
What is the current status of trial NCT00838799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 458 participants. The study started on 2009-02.
What interventions are being tested in trial NCT00838799?
The interventions under investigation include: placebo (DRUG), pregabalin (DRUG), RGH-896 (DRUG).
Who is sponsoring clinical trial NCT00838799?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00838799's enrollment target sits among peer trials
458 84th of 2000 higher than 1,917 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05856942 · 458 participants · NA
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
- NCT06201676 · 458 participants · Phase 4
Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia